Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

Author's Avatar
Jan 19, 2021
Article's Main Image

Tenax Therapeutics, Inc. (Nasdaq: TENX),a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need.